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Objective
Determine the safety and efficacy of photodynamic ther-
apy (PDT) in the treatment of oral leukoplakia with
5-aminolevulinic acid (5-ALA) and pulsed dye laser (PDL).
Methods
A total of 24 subjects, between 18 - 80 years old, with a
confirmed diagnosis of leukoplakia with or without
dysplasia, measuring at least 10 mm in diameter were
enrolled in cohorts of 3 within 24 months. Twenty per-
cent solution of 5-ALA, Levulan KerastickTM were
applied to the lesions, for 1 to 3 hours, by utilizing
custom fixtures made from hygienic polymer. The drug
application was confirmed with Fluorescence diagnosis
system (DyadermTM). High power pulsed dye laser emit-
ting 585-nm wavelength was used to activate the
5-ALA. The laser dose was escalated from 6 to 8 J/cm2.
The safety was evaluated via clinical observation 48
hours post treatment, and the clinical and pathological
efficacy were evaluated 30 and days after treatment,
respectively. Histopathology and immunohistochemistry
were conducted on fixed tissue samples collected at
screening and 90 days post treatments, from the lesion
and an adjacent healthy site.
Results
No significant adverse events and minor pain (3 out of
10) was observed, during and following PDT in the
safety phase of the study. The maximum tolerated dose
was 8 J/cm2. Partial response was observed in 54% of
the treated subjects and significant response was
observed in 46% of the subject treated in the efficacy
phase of the study.
Conclusions
Photodynamic therapy (PDT) with 5-Aminolevulinic
Acid (5-ALA) and PDL could be use to regress oral leu-
koplakia. The treatment is safe and well tolerated. Thick
and progress lesions require multiple treatments. An
application time of 2 hours and laser radiant exposure
of 8 J/cm2 were found to be the best settings, in this
study. The high power laser allows completing the laser
therapy within 1-3 minutes. More work is underway to
determine the optimal laser radiant exposure and drug
application to improve the rate of complete regression.
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